Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial

Mickael Vourc'h, Fanny Feuillet, Pierre-Joachim Mahe, Véronique Sebille, Karim Asehnoune, BACLOREA trial group, Mickael Vourc'h, Fanny Feuillet, Pierre-Joachim Mahe, Véronique Sebille, Karim Asehnoune, BACLOREA trial group

Abstract

Background: Alcohol is the leading psychoactive substance consumed in France, with about 15 million regular consumers. The National institute on Alcohol Abuse and Alcoholism (NIAAA) considers alcohol abuse to be more than 14 units of alcohol a week for men and 7 units for women. The specific complication of alcoholism is the alcohol withdrawal syndrome. Its incidence reaches up to 30 % and its main complications are delirium tremens, restlessness, extended hospital stay, higher morbidity, and psychiatric and cognitive impairment. Without appropriate treatment, delirium tremens can lead to death in up to 50 % of patients.

Methods/design: This prospective, double-blind, randomised controlled study versus placebo will be conducted in twelve French intensive care units (ICU). Patients with an alcohol intake level higher than the NIAAA threshold, who are under mechanical ventilation, will be included. The primary objective is to determine whether baclofen is more efficient than placebo in preventing restlessness-related side effects in the ICU. Secondary outcomes include mechanical ventilation duration, length of ICU stay, and cumulative doses of sedatives and painkillers received within 28 days of ICU admission. Restlessness-related side effects in the ICU are defined as unplanned extubation, medical disposal removal (such as urinary catheter, venous or arterial line or surgical drain), falling out of bed, ICU runaway (leaving ICU without physician's approval), immobilisation device removal, self-aggression or aggression towards medical staff. Daily doses of baclofen/placebo will be guided by daily creatinine clearance assessment.

Discussion: Restlessness in alcoholic patients is a life-threatening issue in ICUs. BACLOREA is a randomised study assessing the capacity of baclofen to prevent agitation in mechanically ventilated patients. Enrolment of 314 patients will begin in June 2016 and is expected to end in October 2018.

Trial registration: ClinicalTrials.gov Identifier: NCT02723383 , registered on 3 March 2016.

Keywords: Alcohol withdrawal syndrome; Alcoholism; Baclofen; Delirium tremens; Intensive care; Restlessness.

References

    1. Alonso J, Ferrer M, Romera B. The European Study of the Epidemiology of Mental Disorders (ESEMeD/MHEDEA 2000) project: rationale and methods. 2002;11(2):55-67. doi:10.1002/mpr.123.
    1. Guerin S, Laplanche A, Dunant A. Alcohol-attributable mortality in France. 2013;23(4):588–93. doi:10.1093/eurpub/ckt015.
    1. Vourc'h G, Hatton F, Tiret L. Epidemiologic study of anesthesia complications in France. Bull Acad Natl Med. 1983;167(8):939–45.
    1. Canarelli T, Cadet A, Palle C. Indicateurs de la morbidité et de la mortalité liées à l'alcool en France. Bull Epidemiol Hebdo. 2006;n°34-35:252–5.
    1. Sanders RD, Pandharipande PP, Davidson AJ, Ma D, Maze M. Anticipating and managing postoperative delirium and cognitive decline in adults. BMJ. 2011;343:d4331. doi: 10.1136/bmj.d4331.
    1. Pandharipande P, Shintani A, Peterson J. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104(1):21–6. doi: 10.1097/00000542-200601000-00005.
    1. Pisani MA, Murphy TE, Araujo KLB, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med. 2009;37(1):177–83. doi: 10.1097/CCM.0b013e318192fcf9.
    1. Lavie P. Sleep disturbances in the wake of traumatic events. N Engl J Med. 2001;345(25):1825–32. doi: 10.1056/NEJMra012893.
    1. Liang C, Chen J, Gu W. Chronic alcoholism increases the induction dose of propofol. Acta Anaesthesiol Scand. 2011;55(9):1113–7. doi: 10.1111/j.1399-6576.2011.02497.x.
    1. Wolfson B, Freed B. Influence of alcohol on anesthetic requirements and acute toxicity. Anesthesia Analg. 1980;59(11):826–30.
    1. Spies CD, Nordmann A, Brummer G, et al. Intensive care unit stay is prolonged in chronic alcoholic men following tumor resection of the upper digestive tract. Acta Anaesthesiol Scand. 1996;40(6):649–56. doi: 10.1111/j.1399-6576.1996.tb04505.x.
    1. Levkoff SE, Evans DA, Liptzin B, et al. Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med. 1992;152(2):334–40. doi: 10.1001/archinte.1992.00400140082019.
    1. Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA. 1990;263(8):1097–101. doi: 10.1001/jama.1990.03440080075027.
    1. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753–62. doi: 10.1001/jama.291.14.1753.
    1. Griffin RE, Gross GA, Teitelbaum HS. Delirium tremens: a review. J Am Osteopath Assoc. 1993;93(9):924–929–32–935.
    1. Kril JJ, Halliday GM. Brain shrinkage in alcoholics: a decade on and what have we learned? Prog Neurobiol. 1999;58(4):381–7. doi: 10.1016/S0301-0082(98)00091-4.
    1. Neiman J. Alcohol as a risk factor for brain damage: neurologic aspects. Alcohol Clin Exp Res. 1998;22(7 Suppl):346S–51. doi: 10.1111/j.1530-0277.1998.tb04389.x.
    1. Gacouin A, Tadie JM, Sauvadet E. At-risk drinking is independently associated with ICU and one-year mortality in critically ill nontrauma patients*. Crit Care Med. 2014;42(4):860–7. doi: 10.1097/CCM.0000000000000041.
    1. Clark BJ, Williams A, Feemster LMC, et al. Alcohol screening scores and 90-day outcomes in patients with acute lung injury. Crit Care Med. 2013;41(6):1518–25. doi: 10.1097/CCM.0b013e318287f1bb.
    1. Tønnesen H, Petersen KR, Højgaard L, et al. Postoperative morbidity among symptom-free alcohol misusers. Lancet. 1992;340(8815):334–7. doi: 10.1016/0140-6736(92)91405-W.
    1. Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006;119(3):276.e13–e18. doi: 10.1016/j.amjmed.2005.08.042.
    1. Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J Hosp Med. 2011;6(8):469–74. doi: 10.1002/jhm.928.
    1. Addolorato G, Leggio L, Ferrulli A, Cardone S. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. The Lancet. 2007;370(9603):1915–1922. doi: 10.1016/S0140-6736(07)61814-5.
    1. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, et al. Dose--response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism. 2011;46(3):312–317. doi:10.1093/alcalc/agr017.
    1. Rigal L, Alexandre-Dubroeucq C, de Beaurepaire R. Abstinence and ‘low-risk’ consumption 1 year after the initiation of high-dose baclofen: a retrospective study among ‘high-risk’ drinkers. Alcohol Alcohol. 2012;47(4):439–42. doi:10.1093/alcalc/ags028.
    1. Riker RR, Fraser GL. The new practice guidelines for pain, agitation, and delirium. Am J Crit Care. 2013;22(2):153–7. doi: 10.4037/ajcc2013480.
    1. Friede T, Kieser M. Sample size recalculation for binary data in internal pilot study designs. Pharm Stat. 2004;3(4):269–79. doi: 10.1002/pst.140.
    1. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biom J. 2006;48(4):537–55. doi: 10.1002/bimj.200510238.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren